


RealRate

PHARMACEUTICAL 2021

Vanda Pharmaceuticals Inc. Rank 16 of 409









PHARMACEUTICAL 2021



RealRate

Vanda Pharmaceuticals Inc. Rank 16 of 409

The relative strengths and weaknesses of Vanda Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vanda Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 357% points. The greatest weakness of Vanda Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 30% points.

The company's Economic Capital Ratio, given in the ranking table, is 193%, being 548% points above the market average of -355%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 409,145 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 21,559 |
| Liabilities, Current | 65,936 |
| Liabilities, Non-Current | 14,254 |
| Other Assets | 98,616 |
| Other Compr. Net Income | -10 |
| Other Expenses | 33,160 |
| Other Liabilities | 0 |
| Other Net Income | 0 |
| Property and Equipment | 4,136 |
| Research and Development | 55,577 |
| Revenues | 252,584 |
| Selling, General and Administrative Expense | 140,510 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 533,456 |
| Liabilities | 80,190 |
| Expenses | 229,247 |
| Stockholders Equity | 453,266 |
| Net Income | 23,337 |
| Comprehensive Net Income | 23,332 |
| Economic Capital Ratio | 193% |

